{"id":"W4401305294","doi":"10.1016/j.annonc.2024.07.727","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Genentech; Astellas Pharma; Eisai; European Society for Medical Oncology; European Association of Urology; Seagen; Advanced Accelerator Applications; National Institutes of Health; CVS Health; Amgen; Deciphera Pharmaceuticals; Jounce Therapeutics; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Merck KGaA; Endocyte; Nihon Pharmaceutical; PTC Therapeutics; BioCryst; Ipsen; Array BioPharma; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Revolution Medicines; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; EUSA Pharma; AstraZeneca; American Society of Clinical Oncology; Coherus Biosciences; Arrowhead Pharmaceuticals; GlaxoSmithKline; Dana-Farber Cancer Institute; Incyte; Pfizer","keywords":"Medicine; Sunitinib; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Oncology; Urology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003744818,0.0008409711,0.001803694,0.0002727744,0.0002763705,0.001048258,0.0006456683,0.0008034192,0.001944171],"category_scores_gemma":[0.002384616,0.0002897898,0.002272058,0.0002877745,0.000472328,0.0006290094,0.0003596637,0.001941704,0.0002968523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009731047,"about_ca_system_score_gemma":0.0008017214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006798944,"about_ca_topic_score_gemma":0.00198532,"domain_scores_codex":[0.999067,0.0006302204,0.00004665985,0.0001116137,0.00007617944,0.00006823539],"domain_scores_gemma":[0.9983066,0.0004969413,0.0006289245,0.0001605821,0.00007172314,0.0003351434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9431651,0.004024304,0.009748951,0.0005398249,0.004834776,0.00005452111,0.0000875011,0.001710621,0.00375742,0.00007688085,0.001251387,0.03074882],"study_design_scores_gemma":[0.722259,0.1729676,0.08167008,0.0001335794,0.01055572,0.0004050228,0.00007430272,0.00451969,0.003575745,0.0004346831,0.003341252,0.00006339878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952008,0.002884928,0.0001928649,0.0002017647,0.00007298931,0.0002121204,0.0005434894,0.00003609585,0.0006549665],"genre_scores_gemma":[0.9963762,0.0008961802,0.0003295184,0.0002300563,0.0001185568,0.0002493768,0.0009815803,0.000009827709,0.0008087442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003744818,"threshold_uncertainty_score":0.01980472,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1106144697575583,"score_gpt":0.3866629650592868,"score_spread":0.2760484953017285,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}